nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—stomach cancer—esophageal cancer	0.129	0.372	CtDrD
Doxorubicin—pancreatic cancer—esophageal cancer	0.12	0.347	CtDrD
Doxorubicin—lung cancer—esophageal cancer	0.0972	0.28	CtDrD
Doxorubicin—NOS3—esophageal cancer	0.0701	0.273	CbGaD
Doxorubicin—NOS2—esophageal cancer	0.0677	0.264	CbGaD
Doxorubicin—CYP1B1—esophageal cancer	0.0576	0.224	CbGaD
Doxorubicin—ABCC2—esophageal cancer	0.0449	0.175	CbGaD
Doxorubicin—NQO1—Carboplatin—esophageal cancer	0.0429	0.178	CbGbCtD
Doxorubicin—NQO1—Cisplatin—esophageal cancer	0.0367	0.152	CbGbCtD
Doxorubicin—ABCC6—Cisplatin—esophageal cancer	0.0307	0.127	CbGbCtD
Doxorubicin—XDH—Carboplatin—esophageal cancer	0.0224	0.0931	CbGbCtD
Doxorubicin—XDH—Cisplatin—esophageal cancer	0.0192	0.0795	CbGbCtD
Doxorubicin—ABCB1—esophageal cancer	0.0165	0.0643	CbGaD
Doxorubicin—ABCC10—Methotrexate—esophageal cancer	0.0152	0.0631	CbGbCtD
Doxorubicin—ABCC3—Cisplatin—esophageal cancer	0.0147	0.0611	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—esophageal cancer	0.00957	0.0397	CbGbCtD
Doxorubicin—ABCC2—Carboplatin—esophageal cancer	0.00784	0.0325	CbGbCtD
Doxorubicin—ABCG2—Carboplatin—esophageal cancer	0.00709	0.0294	CbGbCtD
Doxorubicin—ABCC2—Cisplatin—esophageal cancer	0.0067	0.0278	CbGbCtD
Doxorubicin—ABCG2—Cisplatin—esophageal cancer	0.00606	0.0251	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—esophageal cancer	0.00588	0.0244	CbGbCtD
Doxorubicin—NOS3—thoracic aorta—esophageal cancer	0.00545	0.156	CbGeAlD
Doxorubicin—ABCC2—Methotrexate—esophageal cancer	0.00435	0.018	CbGbCtD
Doxorubicin—CYP2B6—Cisplatin—esophageal cancer	0.00426	0.0177	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—esophageal cancer	0.00393	0.0163	CbGbCtD
Doxorubicin—ABCB1—Cisplatin—esophageal cancer	0.00218	0.00906	CbGbCtD
Doxorubicin—ABCB1—Methotrexate—esophageal cancer	0.00142	0.00588	CbGbCtD
Doxorubicin—CBR3—bronchus—esophageal cancer	0.000724	0.0207	CbGeAlD
Doxorubicin—CBR3—trachea—esophageal cancer	0.00065	0.0186	CbGeAlD
Doxorubicin—AKR1A1—bronchus—esophageal cancer	0.000559	0.016	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—esophageal cancer	0.000547	0.0156	CbGeAlD
Doxorubicin—NDUFS7—bronchus—esophageal cancer	0.000508	0.0145	CbGeAlD
Doxorubicin—AKR1A1—trachea—esophageal cancer	0.000502	0.0143	CbGeAlD
Doxorubicin—ABCB8—lung—esophageal cancer	0.000485	0.0139	CbGeAlD
Doxorubicin—NOS3—neck—esophageal cancer	0.000481	0.0137	CbGeAlD
Doxorubicin—CBR3—lung—esophageal cancer	0.000467	0.0133	CbGeAlD
Doxorubicin—AKR1A1—digestive system—esophageal cancer	0.000432	0.0123	CbGeAlD
Doxorubicin—Daunorubicin—CYP1B1—esophageal cancer	0.00043	0.484	CrCbGaD
Doxorubicin—NOS1—epithelium—esophageal cancer	0.00043	0.0123	CbGeAlD
Doxorubicin—NDUFS2—bronchus—esophageal cancer	0.000421	0.012	CbGeAlD
Doxorubicin—NDUFS3—bronchus—esophageal cancer	0.000416	0.0119	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—esophageal cancer	0.000414	0.0118	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—esophageal cancer	0.000412	0.0118	CbGeAlD
Doxorubicin—NDUFS3—smooth muscle tissue—esophageal cancer	0.000407	0.0116	CbGeAlD
Doxorubicin—DHCR7—bronchus—esophageal cancer	0.000395	0.0113	CbGeAlD
Doxorubicin—NDUFS7—digestive system—esophageal cancer	0.000392	0.0112	CbGeAlD
Doxorubicin—NDUFS2—trachea—esophageal cancer	0.000378	0.0108	CbGeAlD
Doxorubicin—NDUFS3—trachea—esophageal cancer	0.000373	0.0107	CbGeAlD
Doxorubicin—NQO1—neck—esophageal cancer	0.000365	0.0104	CbGeAlD
Doxorubicin—AURKA—digestive system—esophageal cancer	0.000365	0.0104	CbGeAlD
Doxorubicin—YWHAG—bronchus—esophageal cancer	0.000362	0.0103	CbGeAlD
Doxorubicin—AKR1A1—lung—esophageal cancer	0.000361	0.0103	CbGeAlD
Doxorubicin—DHCR7—trachea—esophageal cancer	0.000355	0.0101	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—esophageal cancer	0.000355	0.0101	CbGeAlD
Doxorubicin—Daunorubicin—ABCC2—esophageal cancer	0.000335	0.377	CrCbGaD
Doxorubicin—ABCB8—lymph node—esophageal cancer	0.000332	0.00947	CbGeAlD
Doxorubicin—NDUFS7—lung—esophageal cancer	0.000328	0.00936	CbGeAlD
Doxorubicin—RALBP1—bronchus—esophageal cancer	0.000327	0.00935	CbGeAlD
Doxorubicin—NOS1—digestive system—esophageal cancer	0.000327	0.00934	CbGeAlD
Doxorubicin—NOS3—epithelium—esophageal cancer	0.000327	0.00934	CbGeAlD
Doxorubicin—YWHAG—trachea—esophageal cancer	0.000325	0.00929	CbGeAlD
Doxorubicin—NDUFS2—digestive system—esophageal cancer	0.000325	0.00928	CbGeAlD
Doxorubicin—NDUFS3—digestive system—esophageal cancer	0.000321	0.00917	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—esophageal cancer	0.00032	0.00914	CbGeAlD
Doxorubicin—CBR3—lymph node—esophageal cancer	0.000319	0.00912	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—esophageal cancer	0.000315	0.009	CbGeAlD
Doxorubicin—CBR1—bronchus—esophageal cancer	0.000306	0.00872	CbGeAlD
Doxorubicin—DHCR7—digestive system—esophageal cancer	0.000305	0.00871	CbGeAlD
Doxorubicin—AURKA—lung—esophageal cancer	0.000305	0.0087	CbGeAlD
Doxorubicin—AKR1C3—bronchus—esophageal cancer	0.000302	0.00862	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—esophageal cancer	0.000295	0.00843	CbGeAlD
Doxorubicin—RALBP1—trachea—esophageal cancer	0.000294	0.00839	CbGeAlD
Doxorubicin—NOS3—trachea—esophageal cancer	0.000289	0.00826	CbGeAlD
Doxorubicin—YWHAG—digestive system—esophageal cancer	0.00028	0.00799	CbGeAlD
Doxorubicin—POR—bronchus—esophageal cancer	0.000276	0.00787	CbGeAlD
Doxorubicin—CBR1—trachea—esophageal cancer	0.000274	0.00783	CbGeAlD
Doxorubicin—NOS1—lung—esophageal cancer	0.000273	0.0078	CbGeAlD
Doxorubicin—XDH—digestive system—esophageal cancer	0.000273	0.0078	CbGeAlD
Doxorubicin—NDUFS2—lung—esophageal cancer	0.000272	0.00775	CbGeAlD
Doxorubicin—AKR1C3—trachea—esophageal cancer	0.000271	0.00774	CbGeAlD
Doxorubicin—NDUFS3—lung—esophageal cancer	0.000268	0.00766	CbGeAlD
Doxorubicin—ABCB11—digestive system—esophageal cancer	0.000267	0.00762	CbGeAlD
Doxorubicin—TOP2A—bronchus—esophageal cancer	0.000257	0.00733	CbGeAlD
Doxorubicin—DHCR7—lung—esophageal cancer	0.000255	0.00728	CbGeAlD
Doxorubicin—RALBP1—digestive system—esophageal cancer	0.000253	0.00722	CbGeAlD
Doxorubicin—NOS3—digestive system—esophageal cancer	0.000249	0.0071	CbGeAlD
Doxorubicin—NQO1—epithelium—esophageal cancer	0.000249	0.0071	CbGeAlD
Doxorubicin—ABCC6—lung—esophageal cancer	0.000248	0.00709	CbGeAlD
Doxorubicin—POR—trachea—esophageal cancer	0.000247	0.00706	CbGeAlD
Doxorubicin—AKR1A1—lymph node—esophageal cancer	0.000247	0.00704	CbGeAlD
Doxorubicin—NQO1—bronchus—esophageal cancer	0.000245	0.00699	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—esophageal cancer	0.00024	0.00684	CbGeAlD
Doxorubicin—CBR1—digestive system—esophageal cancer	0.000236	0.00674	CbGeAlD
Doxorubicin—YWHAG—lung—esophageal cancer	0.000234	0.00668	CbGeAlD
Doxorubicin—NDUFS7—lymph node—esophageal cancer	0.000224	0.0064	CbGeAlD
Doxorubicin—NQO1—trachea—esophageal cancer	0.00022	0.00628	CbGeAlD
Doxorubicin—ABCC10—bronchus—esophageal cancer	0.000219	0.00624	CbGeAlD
Doxorubicin—RALBP1—lung—esophageal cancer	0.000211	0.00603	CbGeAlD
Doxorubicin—AURKA—lymph node—esophageal cancer	0.000208	0.00595	CbGeAlD
Doxorubicin—NOS3—lung—esophageal cancer	0.000208	0.00593	CbGeAlD
Doxorubicin—CBR1—lung—esophageal cancer	0.000197	0.00563	CbGeAlD
Doxorubicin—ABCC10—trachea—esophageal cancer	0.000196	0.00561	CbGeAlD
Doxorubicin—AKR1C3—lung—esophageal cancer	0.000195	0.00556	CbGeAlD
Doxorubicin—NQO1—digestive system—esophageal cancer	0.000189	0.0054	CbGeAlD
Doxorubicin—NDUFS2—lymph node—esophageal cancer	0.000186	0.0053	CbGeAlD
Doxorubicin—NDUFS3—lymph node—esophageal cancer	0.000183	0.00524	CbGeAlD
Doxorubicin—POR—lung—esophageal cancer	0.000178	0.00508	CbGeAlD
Doxorubicin—DHCR7—lymph node—esophageal cancer	0.000174	0.00498	CbGeAlD
Doxorubicin—ABCC3—digestive system—esophageal cancer	0.00017	0.00485	CbGeAlD
Doxorubicin—ABCC10—digestive system—esophageal cancer	0.000169	0.00482	CbGeAlD
Doxorubicin—CYP1B1—smooth muscle tissue—esophageal cancer	0.000168	0.0048	CbGeAlD
Doxorubicin—TOP2A—lung—esophageal cancer	0.000166	0.00473	CbGeAlD
Doxorubicin—YWHAG—lymph node—esophageal cancer	0.00016	0.00457	CbGeAlD
Doxorubicin—NQO1—lung—esophageal cancer	0.000158	0.00451	CbGeAlD
Doxorubicin—ABCC1—bronchus—esophageal cancer	0.000155	0.00442	CbGeAlD
Doxorubicin—RALBP1—lymph node—esophageal cancer	0.000144	0.00412	CbGeAlD
Doxorubicin—NOS3—lymph node—esophageal cancer	0.000142	0.00406	CbGeAlD
Doxorubicin—ABCC3—lung—esophageal cancer	0.000142	0.00405	CbGeAlD
Doxorubicin—ABCC10—lung—esophageal cancer	0.000141	0.00403	CbGeAlD
Doxorubicin—ABCC1—trachea—esophageal cancer	0.000139	0.00396	CbGeAlD
Doxorubicin—ABCC2—digestive system—esophageal cancer	0.000136	0.00387	CbGeAlD
Doxorubicin—CBR1—lymph node—esophageal cancer	0.000135	0.00385	CbGeAlD
Doxorubicin—AKR1C3—lymph node—esophageal cancer	0.000133	0.0038	CbGeAlD
Doxorubicin—CYP1B1—digestive system—esophageal cancer	0.000133	0.00379	CbGeAlD
Doxorubicin—Daunorubicin—ABCB1—esophageal cancer	0.000123	0.139	CrCbGaD
Doxorubicin—POR—lymph node—esophageal cancer	0.000122	0.00347	CbGeAlD
Doxorubicin—CYP2B6—bronchus—esophageal cancer	0.000118	0.00337	CbGeAlD
Doxorubicin—TOP2A—lymph node—esophageal cancer	0.000113	0.00324	CbGeAlD
Doxorubicin—CYP1B1—lung—esophageal cancer	0.000111	0.00317	CbGeAlD
Doxorubicin—NQO1—lymph node—esophageal cancer	0.000108	0.00308	CbGeAlD
Doxorubicin—ABCC1—lung—esophageal cancer	9.98e-05	0.00285	CbGeAlD
Doxorubicin—ABCC3—lymph node—esophageal cancer	9.69e-05	0.00277	CbGeAlD
Doxorubicin—ABCC10—lymph node—esophageal cancer	9.65e-05	0.00275	CbGeAlD
Doxorubicin—CYP2B6—digestive system—esophageal cancer	9.12e-05	0.00261	CbGeAlD
Doxorubicin—ABCG2—lung—esophageal cancer	8.26e-05	0.00236	CbGeAlD
Doxorubicin—ABCC2—lymph node—esophageal cancer	7.75e-05	0.00221	CbGeAlD
Doxorubicin—CYP2B6—lung—esophageal cancer	7.62e-05	0.00218	CbGeAlD
Doxorubicin—CYP1B1—lymph node—esophageal cancer	7.59e-05	0.00217	CbGeAlD
Doxorubicin—CYP3A4—digestive system—esophageal cancer	6.89e-05	0.00197	CbGeAlD
Doxorubicin—ABCC1—lymph node—esophageal cancer	6.82e-05	0.00195	CbGeAlD
Doxorubicin—CYP2D6—digestive system—esophageal cancer	6.78e-05	0.00194	CbGeAlD
Doxorubicin—ABCB1—epithelium—esophageal cancer	6.41e-05	0.00183	CbGeAlD
Doxorubicin—ABCB1—trachea—esophageal cancer	5.67e-05	0.00162	CbGeAlD
Doxorubicin—ABCG2—lymph node—esophageal cancer	5.65e-05	0.00161	CbGeAlD
Doxorubicin—Angina pectoris—Capecitabine—esophageal cancer	5.57e-05	0.000963	CcSEcCtD
Doxorubicin—Arrhythmia—Cisplatin—esophageal cancer	5.54e-05	0.000959	CcSEcCtD
Doxorubicin—Bronchitis—Capecitabine—esophageal cancer	5.5e-05	0.000951	CcSEcCtD
Doxorubicin—Alopecia—Cisplatin—esophageal cancer	5.48e-05	0.000949	CcSEcCtD
Doxorubicin—Hepatic failure—Methotrexate—esophageal cancer	5.48e-05	0.000947	CcSEcCtD
Doxorubicin—Pancytopenia—Capecitabine—esophageal cancer	5.43e-05	0.000939	CcSEcCtD
Doxorubicin—Malnutrition—Cisplatin—esophageal cancer	5.4e-05	0.000934	CcSEcCtD
Doxorubicin—Erythema—Cisplatin—esophageal cancer	5.4e-05	0.000934	CcSEcCtD
Doxorubicin—Neutropenia—Capecitabine—esophageal cancer	5.34e-05	0.000924	CcSEcCtD
Doxorubicin—Dysuria—Capecitabine—esophageal cancer	5.34e-05	0.000924	CcSEcCtD
Doxorubicin—Renal failure acute—Methotrexate—esophageal cancer	5.33e-05	0.000922	CcSEcCtD
Doxorubicin—Flatulence—Cisplatin—esophageal cancer	5.32e-05	0.000921	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Capecitabine—esophageal cancer	5.31e-05	0.000919	CcSEcCtD
Doxorubicin—Dermatitis exfoliative—Methotrexate—esophageal cancer	5.22e-05	0.000902	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Capecitabine—esophageal cancer	5.22e-05	0.000902	CcSEcCtD
Doxorubicin—Weight increased—Capecitabine—esophageal cancer	5.2e-05	0.0009	CcSEcCtD
Doxorubicin—Muscle spasms—Cisplatin—esophageal cancer	5.19e-05	0.000898	CcSEcCtD
Doxorubicin—Weight decreased—Capecitabine—esophageal cancer	5.17e-05	0.000894	CcSEcCtD
Doxorubicin—Hyperglycaemia—Capecitabine—esophageal cancer	5.16e-05	0.000892	CcSEcCtD
Doxorubicin—Pneumonia—Capecitabine—esophageal cancer	5.13e-05	0.000887	CcSEcCtD
Doxorubicin—Infestation NOS—Capecitabine—esophageal cancer	5.1e-05	0.000881	CcSEcCtD
Doxorubicin—Infestation—Capecitabine—esophageal cancer	5.1e-05	0.000881	CcSEcCtD
Doxorubicin—Vision blurred—Cisplatin—esophageal cancer	5.09e-05	0.000881	CcSEcCtD
Doxorubicin—Anaphylactoid reaction—Methotrexate—esophageal cancer	5.09e-05	0.00088	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	5.05e-05	0.000874	CcSEcCtD
Doxorubicin—Cerebrovascular accident—Methotrexate—esophageal cancer	5.02e-05	0.000869	CcSEcCtD
Doxorubicin—Lethargy—Methotrexate—esophageal cancer	5.02e-05	0.000869	CcSEcCtD
Doxorubicin—Ill-defined disorder—Cisplatin—esophageal cancer	5.01e-05	0.000867	CcSEcCtD
Doxorubicin—Renal failure—Capecitabine—esophageal cancer	5.01e-05	0.000866	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Capecitabine—esophageal cancer	5e-05	0.000864	CcSEcCtD
Doxorubicin—Anaemia—Cisplatin—esophageal cancer	4.99e-05	0.000864	CcSEcCtD
Doxorubicin—Jaundice—Capecitabine—esophageal cancer	4.97e-05	0.000859	CcSEcCtD
Doxorubicin—Stomatitis—Capecitabine—esophageal cancer	4.97e-05	0.000859	CcSEcCtD
Doxorubicin—Urinary tract infection—Capecitabine—esophageal cancer	4.95e-05	0.000857	CcSEcCtD
Doxorubicin—Conjunctivitis—Capecitabine—esophageal cancer	4.95e-05	0.000857	CcSEcCtD
Doxorubicin—Osteoarthritis—Methotrexate—esophageal cancer	4.92e-05	0.000851	CcSEcCtD
Doxorubicin—ABCB1—digestive system—esophageal cancer	4.88e-05	0.00139	CbGeAlD
Doxorubicin—Malaise—Cisplatin—esophageal cancer	4.87e-05	0.000843	CcSEcCtD
Doxorubicin—Haematuria—Capecitabine—esophageal cancer	4.86e-05	0.00084	CcSEcCtD
Doxorubicin—Leukopenia—Cisplatin—esophageal cancer	4.84e-05	0.000836	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Capecitabine—esophageal cancer	4.82e-05	0.000834	CcSEcCtD
Doxorubicin—Epistaxis—Capecitabine—esophageal cancer	4.81e-05	0.000831	CcSEcCtD
Doxorubicin—Agranulocytosis—Capecitabine—esophageal cancer	4.76e-05	0.000823	CcSEcCtD
Doxorubicin—Convulsion—Cisplatin—esophageal cancer	4.68e-05	0.00081	CcSEcCtD
Doxorubicin—Mood swings—Methotrexate—esophageal cancer	4.66e-05	0.000807	CcSEcCtD
Doxorubicin—Bradycardia—Capecitabine—esophageal cancer	4.66e-05	0.000805	CcSEcCtD
Doxorubicin—Ataxia—Methotrexate—esophageal cancer	4.63e-05	0.000801	CcSEcCtD
Doxorubicin—Myalgia—Cisplatin—esophageal cancer	4.6e-05	0.000795	CcSEcCtD
Doxorubicin—Haemoglobin—Capecitabine—esophageal cancer	4.6e-05	0.000795	CcSEcCtD
Doxorubicin—Rhinitis—Capecitabine—esophageal cancer	4.59e-05	0.000793	CcSEcCtD
Doxorubicin—Anxiety—Cisplatin—esophageal cancer	4.58e-05	0.000793	CcSEcCtD
Doxorubicin—Hepatitis—Capecitabine—esophageal cancer	4.57e-05	0.000791	CcSEcCtD
Doxorubicin—Haemorrhage—Capecitabine—esophageal cancer	4.57e-05	0.000791	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	4.57e-05	0.00079	CcSEcCtD
Doxorubicin—Hypoaesthesia—Capecitabine—esophageal cancer	4.55e-05	0.000787	CcSEcCtD
Doxorubicin—Liver function test abnormal—Methotrexate—esophageal cancer	4.54e-05	0.000786	CcSEcCtD
Doxorubicin—Discomfort—Cisplatin—esophageal cancer	4.54e-05	0.000786	CcSEcCtD
Doxorubicin—Pharyngitis—Capecitabine—esophageal cancer	4.54e-05	0.000785	CcSEcCtD
Doxorubicin—Urinary tract disorder—Capecitabine—esophageal cancer	4.52e-05	0.000781	CcSEcCtD
Doxorubicin—Oedema peripheral—Capecitabine—esophageal cancer	4.51e-05	0.000779	CcSEcCtD
Doxorubicin—Connective tissue disorder—Capecitabine—esophageal cancer	4.5e-05	0.000778	CcSEcCtD
Doxorubicin—Urethral disorder—Capecitabine—esophageal cancer	4.48e-05	0.000776	CcSEcCtD
Doxorubicin—Breast disorder—Methotrexate—esophageal cancer	4.45e-05	0.000769	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	4.43e-05	0.000767	CcSEcCtD
Doxorubicin—Oedema—Cisplatin—esophageal cancer	4.41e-05	0.000763	CcSEcCtD
Doxorubicin—Anaphylactic shock—Cisplatin—esophageal cancer	4.41e-05	0.000763	CcSEcCtD
Doxorubicin—Visual impairment—Capecitabine—esophageal cancer	4.41e-05	0.000763	CcSEcCtD
Doxorubicin—Infection—Cisplatin—esophageal cancer	4.38e-05	0.000758	CcSEcCtD
Doxorubicin—Erythema multiforme—Capecitabine—esophageal cancer	4.33e-05	0.000748	CcSEcCtD
Doxorubicin—Nervous system disorder—Cisplatin—esophageal cancer	4.32e-05	0.000748	CcSEcCtD
Doxorubicin—Thrombocytopenia—Cisplatin—esophageal cancer	4.32e-05	0.000747	CcSEcCtD
Doxorubicin—Tachycardia—Cisplatin—esophageal cancer	4.3e-05	0.000744	CcSEcCtD
Doxorubicin—Skin disorder—Cisplatin—esophageal cancer	4.28e-05	0.000741	CcSEcCtD
Doxorubicin—Eye disorder—Capecitabine—esophageal cancer	4.28e-05	0.000739	CcSEcCtD
Doxorubicin—Tinnitus—Capecitabine—esophageal cancer	4.27e-05	0.000738	CcSEcCtD
Doxorubicin—Hyperhidrosis—Cisplatin—esophageal cancer	4.26e-05	0.000737	CcSEcCtD
Doxorubicin—Asthma—Methotrexate—esophageal cancer	4.25e-05	0.000736	CcSEcCtD
Doxorubicin—Flushing—Capecitabine—esophageal cancer	4.25e-05	0.000734	CcSEcCtD
Doxorubicin—Cardiac disorder—Capecitabine—esophageal cancer	4.25e-05	0.000734	CcSEcCtD
Doxorubicin—Eosinophilia—Methotrexate—esophageal cancer	4.21e-05	0.000729	CcSEcCtD
Doxorubicin—Anorexia—Cisplatin—esophageal cancer	4.2e-05	0.000727	CcSEcCtD
Doxorubicin—Pancreatitis—Methotrexate—esophageal cancer	4.17e-05	0.000721	CcSEcCtD
Doxorubicin—Angiopathy—Capecitabine—esophageal cancer	4.15e-05	0.000718	CcSEcCtD
Doxorubicin—Immune system disorder—Capecitabine—esophageal cancer	4.13e-05	0.000715	CcSEcCtD
Doxorubicin—Mediastinal disorder—Capecitabine—esophageal cancer	4.12e-05	0.000713	CcSEcCtD
Doxorubicin—Hypotension—Cisplatin—esophageal cancer	4.12e-05	0.000713	CcSEcCtD
Doxorubicin—Chills—Capecitabine—esophageal cancer	4.1e-05	0.00071	CcSEcCtD
Doxorubicin—Arrhythmia—Capecitabine—esophageal cancer	4.09e-05	0.000707	CcSEcCtD
Doxorubicin—ABCB1—lung—esophageal cancer	4.07e-05	0.00116	CbGeAlD
Doxorubicin—Alopecia—Capecitabine—esophageal cancer	4.04e-05	0.000699	CcSEcCtD
Doxorubicin—Pancytopenia—Methotrexate—esophageal cancer	4.04e-05	0.000699	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	4.02e-05	0.000695	CcSEcCtD
Doxorubicin—Mental disorder—Capecitabine—esophageal cancer	4.01e-05	0.000693	CcSEcCtD
Doxorubicin—Erythema—Capecitabine—esophageal cancer	3.98e-05	0.000689	CcSEcCtD
Doxorubicin—Malnutrition—Capecitabine—esophageal cancer	3.98e-05	0.000689	CcSEcCtD
Doxorubicin—Dysuria—Methotrexate—esophageal cancer	3.98e-05	0.000688	CcSEcCtD
Doxorubicin—Neutropenia—Methotrexate—esophageal cancer	3.98e-05	0.000688	CcSEcCtD
Doxorubicin—Paraesthesia—Cisplatin—esophageal cancer	3.96e-05	0.000685	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Methotrexate—esophageal cancer	3.95e-05	0.000684	CcSEcCtD
Doxorubicin—Dyspnoea—Cisplatin—esophageal cancer	3.93e-05	0.00068	CcSEcCtD
Doxorubicin—Flatulence—Capecitabine—esophageal cancer	3.92e-05	0.000679	CcSEcCtD
Doxorubicin—Dysgeusia—Capecitabine—esophageal cancer	3.9e-05	0.000675	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Methotrexate—esophageal cancer	3.88e-05	0.000672	CcSEcCtD
Doxorubicin—Back pain—Capecitabine—esophageal cancer	3.85e-05	0.000666	CcSEcCtD
Doxorubicin—Decreased appetite—Cisplatin—esophageal cancer	3.83e-05	0.000663	CcSEcCtD
Doxorubicin—Muscle spasms—Capecitabine—esophageal cancer	3.83e-05	0.000662	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—esophageal cancer	3.82e-05	0.00066	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Cisplatin—esophageal cancer	3.81e-05	0.000658	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—esophageal cancer	3.79e-05	0.000656	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—esophageal cancer	3.79e-05	0.000656	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—esophageal cancer	3.79e-05	0.000656	CcSEcCtD
Doxorubicin—Pain—Cisplatin—esophageal cancer	3.77e-05	0.000652	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	3.76e-05	0.00065	CcSEcCtD
Doxorubicin—Vision blurred—Capecitabine—esophageal cancer	3.75e-05	0.000649	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—esophageal cancer	3.73e-05	0.000645	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—esophageal cancer	3.7e-05	0.00064	CcSEcCtD
Doxorubicin—Ill-defined disorder—Capecitabine—esophageal cancer	3.69e-05	0.000639	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—esophageal cancer	3.69e-05	0.000638	CcSEcCtD
Doxorubicin—Anaemia—Capecitabine—esophageal cancer	3.68e-05	0.000637	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—esophageal cancer	3.64e-05	0.000629	CcSEcCtD
Doxorubicin—Feeling abnormal—Cisplatin—esophageal cancer	3.63e-05	0.000628	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—esophageal cancer	3.62e-05	0.000626	CcSEcCtD
Doxorubicin—Malaise—Capecitabine—esophageal cancer	3.59e-05	0.000621	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—esophageal cancer	3.59e-05	0.000621	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—esophageal cancer	3.58e-05	0.000619	CcSEcCtD
Doxorubicin—Vertigo—Capecitabine—esophageal cancer	3.58e-05	0.000619	CcSEcCtD
Doxorubicin—Syncope—Capecitabine—esophageal cancer	3.57e-05	0.000618	CcSEcCtD
Doxorubicin—Leukopenia—Capecitabine—esophageal cancer	3.56e-05	0.000617	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—esophageal cancer	3.54e-05	0.000612	CcSEcCtD
Doxorubicin—Palpitations—Capecitabine—esophageal cancer	3.52e-05	0.000609	CcSEcCtD
Doxorubicin—Loss of consciousness—Capecitabine—esophageal cancer	3.5e-05	0.000605	CcSEcCtD
Doxorubicin—Body temperature increased—Cisplatin—esophageal cancer	3.49e-05	0.000603	CcSEcCtD
Doxorubicin—Cough—Capecitabine—esophageal cancer	3.47e-05	0.000601	CcSEcCtD
Doxorubicin—Hypertension—Capecitabine—esophageal cancer	3.44e-05	0.000595	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—esophageal cancer	3.42e-05	0.000592	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—esophageal cancer	3.41e-05	0.000589	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—esophageal cancer	3.41e-05	0.000589	CcSEcCtD
Doxorubicin—Chest pain—Capecitabine—esophageal cancer	3.39e-05	0.000586	CcSEcCtD
Doxorubicin—Myalgia—Capecitabine—esophageal cancer	3.39e-05	0.000586	CcSEcCtD
Doxorubicin—Arthralgia—Capecitabine—esophageal cancer	3.39e-05	0.000586	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—esophageal cancer	3.38e-05	0.000585	CcSEcCtD
Doxorubicin—Anxiety—Capecitabine—esophageal cancer	3.38e-05	0.000584	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	3.37e-05	0.000582	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—esophageal cancer	3.36e-05	0.000582	CcSEcCtD
Doxorubicin—Discomfort—Capecitabine—esophageal cancer	3.35e-05	0.000579	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—esophageal cancer	3.34e-05	0.000577	CcSEcCtD
Doxorubicin—Dry mouth—Capecitabine—esophageal cancer	3.32e-05	0.000573	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—esophageal cancer	3.28e-05	0.000568	CcSEcCtD
Doxorubicin—Confusional state—Capecitabine—esophageal cancer	3.28e-05	0.000567	CcSEcCtD
Doxorubicin—Oedema—Capecitabine—esophageal cancer	3.25e-05	0.000562	CcSEcCtD
Doxorubicin—Hypersensitivity—Cisplatin—esophageal cancer	3.25e-05	0.000562	CcSEcCtD
Doxorubicin—Infection—Capecitabine—esophageal cancer	3.23e-05	0.000558	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—esophageal cancer	3.22e-05	0.000557	CcSEcCtD
Doxorubicin—Shock—Capecitabine—esophageal cancer	3.2e-05	0.000553	CcSEcCtD
Doxorubicin—Nervous system disorder—Capecitabine—esophageal cancer	3.19e-05	0.000551	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—esophageal cancer	3.18e-05	0.00055	CcSEcCtD
Doxorubicin—Thrombocytopenia—Capecitabine—esophageal cancer	3.18e-05	0.00055	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—esophageal cancer	3.18e-05	0.000549	CcSEcCtD
Doxorubicin—Tachycardia—Capecitabine—esophageal cancer	3.17e-05	0.000549	CcSEcCtD
Doxorubicin—Asthenia—Cisplatin—esophageal cancer	3.16e-05	0.000547	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—esophageal cancer	3.16e-05	0.000547	CcSEcCtD
Doxorubicin—Skin disorder—Capecitabine—esophageal cancer	3.16e-05	0.000546	CcSEcCtD
Doxorubicin—Hyperhidrosis—Capecitabine—esophageal cancer	3.14e-05	0.000543	CcSEcCtD
Doxorubicin—Anorexia—Capecitabine—esophageal cancer	3.1e-05	0.000536	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—esophageal cancer	3.09e-05	0.000534	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—esophageal cancer	3.08e-05	0.000532	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—esophageal cancer	3.07e-05	0.000531	CcSEcCtD
Doxorubicin—Chills—Methotrexate—esophageal cancer	3.06e-05	0.000529	CcSEcCtD
Doxorubicin—Hypotension—Capecitabine—esophageal cancer	3.04e-05	0.000525	CcSEcCtD
Doxorubicin—Diarrhoea—Cisplatin—esophageal cancer	3.02e-05	0.000522	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—esophageal cancer	3.01e-05	0.00052	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—esophageal cancer	2.98e-05	0.000516	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—esophageal cancer	2.96e-05	0.000513	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—esophageal cancer	2.96e-05	0.000513	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	2.96e-05	0.000512	CcSEcCtD
Doxorubicin—Insomnia—Capecitabine—esophageal cancer	2.94e-05	0.000508	CcSEcCtD
Doxorubicin—Paraesthesia—Capecitabine—esophageal cancer	2.92e-05	0.000505	CcSEcCtD
Doxorubicin—Dysgeusia—Methotrexate—esophageal cancer	2.9e-05	0.000502	CcSEcCtD
Doxorubicin—Dyspnoea—Capecitabine—esophageal cancer	2.9e-05	0.000501	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—esophageal cancer	2.87e-05	0.000496	CcSEcCtD
Doxorubicin—Dyspepsia—Capecitabine—esophageal cancer	2.86e-05	0.000495	CcSEcCtD
Doxorubicin—Decreased appetite—Capecitabine—esophageal cancer	2.83e-05	0.000489	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Capecitabine—esophageal cancer	2.81e-05	0.000485	CcSEcCtD
Doxorubicin—Vomiting—Cisplatin—esophageal cancer	2.8e-05	0.000485	CcSEcCtD
Doxorubicin—Fatigue—Capecitabine—esophageal cancer	2.8e-05	0.000485	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—esophageal cancer	2.79e-05	0.000483	CcSEcCtD
Doxorubicin—ABCB1—lymph node—esophageal cancer	2.79e-05	0.000795	CbGeAlD
Doxorubicin—Rash—Cisplatin—esophageal cancer	2.78e-05	0.000481	CcSEcCtD
Doxorubicin—Constipation—Capecitabine—esophageal cancer	2.78e-05	0.000481	CcSEcCtD
Doxorubicin—Pain—Capecitabine—esophageal cancer	2.78e-05	0.000481	CcSEcCtD
Doxorubicin—Dermatitis—Cisplatin—esophageal cancer	2.78e-05	0.00048	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—esophageal cancer	2.75e-05	0.000476	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—esophageal cancer	2.74e-05	0.000474	CcSEcCtD
Doxorubicin—Feeling abnormal—Capecitabine—esophageal cancer	2.68e-05	0.000463	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—esophageal cancer	2.67e-05	0.000462	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—esophageal cancer	2.66e-05	0.000461	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Capecitabine—esophageal cancer	2.66e-05	0.00046	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—esophageal cancer	2.65e-05	0.000459	CcSEcCtD
Doxorubicin—Nausea—Cisplatin—esophageal cancer	2.62e-05	0.000453	CcSEcCtD
Doxorubicin—Cough—Methotrexate—esophageal cancer	2.59e-05	0.000447	CcSEcCtD
Doxorubicin—Urticaria—Capecitabine—esophageal cancer	2.58e-05	0.000447	CcSEcCtD
Doxorubicin—Abdominal pain—Capecitabine—esophageal cancer	2.57e-05	0.000444	CcSEcCtD
Doxorubicin—Body temperature increased—Capecitabine—esophageal cancer	2.57e-05	0.000444	CcSEcCtD
Doxorubicin—Convulsion—Methotrexate—esophageal cancer	2.57e-05	0.000444	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—esophageal cancer	2.52e-05	0.000437	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—esophageal cancer	2.52e-05	0.000437	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—esophageal cancer	2.52e-05	0.000437	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	2.51e-05	0.000434	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—esophageal cancer	2.49e-05	0.000431	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—esophageal cancer	2.44e-05	0.000422	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—esophageal cancer	2.42e-05	0.000418	CcSEcCtD
Doxorubicin—Infection—Methotrexate—esophageal cancer	2.4e-05	0.000416	CcSEcCtD
Doxorubicin—Hypersensitivity—Capecitabine—esophageal cancer	2.39e-05	0.000414	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—esophageal cancer	2.37e-05	0.00041	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—esophageal cancer	2.37e-05	0.00041	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—esophageal cancer	2.35e-05	0.000406	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—esophageal cancer	2.34e-05	0.000405	CcSEcCtD
Doxorubicin—Asthenia—Capecitabine—esophageal cancer	2.33e-05	0.000403	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—esophageal cancer	2.31e-05	0.000399	CcSEcCtD
Doxorubicin—Pruritus—Capecitabine—esophageal cancer	2.3e-05	0.000398	CcSEcCtD
Doxorubicin—Hypotension—Methotrexate—esophageal cancer	2.26e-05	0.000391	CcSEcCtD
Doxorubicin—Diarrhoea—Capecitabine—esophageal cancer	2.22e-05	0.000385	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	2.2e-05	0.000381	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—esophageal cancer	2.19e-05	0.000378	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—esophageal cancer	2.17e-05	0.000376	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—esophageal cancer	2.16e-05	0.000373	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—esophageal cancer	2.15e-05	0.000372	CcSEcCtD
Doxorubicin—Dizziness—Capecitabine—esophageal cancer	2.15e-05	0.000372	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—esophageal cancer	2.13e-05	0.000368	CcSEcCtD
Doxorubicin—Decreased appetite—Methotrexate—esophageal cancer	2.1e-05	0.000364	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Methotrexate—esophageal cancer	2.09e-05	0.000361	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—esophageal cancer	2.09e-05	0.000361	CcSEcCtD
Doxorubicin—Pain—Methotrexate—esophageal cancer	2.07e-05	0.000358	CcSEcCtD
Doxorubicin—Vomiting—Capecitabine—esophageal cancer	2.07e-05	0.000357	CcSEcCtD
Doxorubicin—Rash—Capecitabine—esophageal cancer	2.05e-05	0.000354	CcSEcCtD
Doxorubicin—Dermatitis—Capecitabine—esophageal cancer	2.05e-05	0.000354	CcSEcCtD
Doxorubicin—Headache—Capecitabine—esophageal cancer	2.04e-05	0.000352	CcSEcCtD
Doxorubicin—Feeling abnormal—Methotrexate—esophageal cancer	1.99e-05	0.000345	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—esophageal cancer	1.98e-05	0.000342	CcSEcCtD
Doxorubicin—Nausea—Capecitabine—esophageal cancer	1.93e-05	0.000334	CcSEcCtD
Doxorubicin—Urticaria—Methotrexate—esophageal cancer	1.92e-05	0.000332	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—esophageal cancer	1.91e-05	0.000331	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—esophageal cancer	1.91e-05	0.000331	CcSEcCtD
Doxorubicin—Hypersensitivity—Methotrexate—esophageal cancer	1.78e-05	0.000308	CcSEcCtD
Doxorubicin—Asthenia—Methotrexate—esophageal cancer	1.74e-05	0.0003	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—esophageal cancer	1.71e-05	0.000296	CcSEcCtD
Doxorubicin—Diarrhoea—Methotrexate—esophageal cancer	1.66e-05	0.000286	CcSEcCtD
Doxorubicin—Dizziness—Methotrexate—esophageal cancer	1.6e-05	0.000277	CcSEcCtD
Doxorubicin—Vomiting—Methotrexate—esophageal cancer	1.54e-05	0.000266	CcSEcCtD
Doxorubicin—Rash—Methotrexate—esophageal cancer	1.53e-05	0.000264	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—esophageal cancer	1.52e-05	0.000264	CcSEcCtD
Doxorubicin—Headache—Methotrexate—esophageal cancer	1.52e-05	0.000262	CcSEcCtD
Doxorubicin—Nausea—Methotrexate—esophageal cancer	1.44e-05	0.000249	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—KDR—esophageal cancer	2.45e-06	3.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTGS2—esophageal cancer	2.45e-06	3.97e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTO1—esophageal cancer	2.45e-06	3.97e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TPI1—esophageal cancer	2.45e-06	3.97e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.44e-06	3.96e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFBR2—esophageal cancer	2.44e-06	3.95e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS1—esophageal cancer	2.43e-06	3.93e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ENO1—esophageal cancer	2.43e-06	3.93e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.43e-06	3.93e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CA2—esophageal cancer	2.42e-06	3.91e-05	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PIK3CA—esophageal cancer	2.4e-06	3.9e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PSME2—esophageal cancer	2.39e-06	3.87e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PSME1—esophageal cancer	2.39e-06	3.87e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ADH7—esophageal cancer	2.38e-06	3.86e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PLCE1—esophageal cancer	2.38e-06	3.86e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.37e-06	3.85e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.36e-06	3.83e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALDOB—esophageal cancer	2.35e-06	3.8e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP1B1—esophageal cancer	2.35e-06	3.8e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CDKN1A—esophageal cancer	2.33e-06	3.78e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CREBBP—esophageal cancer	2.33e-06	3.78e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—NOS3—esophageal cancer	2.33e-06	3.77e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NOTCH1—esophageal cancer	2.31e-06	3.75e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SMAD4—esophageal cancer	2.31e-06	3.74e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.3e-06	3.72e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GAPDH—esophageal cancer	2.26e-06	3.66e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.25e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLCE1—esophageal cancer	2.25e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ADH7—esophageal cancer	2.25e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MYC—esophageal cancer	2.25e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—NOS3—esophageal cancer	2.24e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PIK3CA—esophageal cancer	2.24e-06	3.63e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CRABP1—esophageal cancer	2.24e-06	3.63e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EP300—esophageal cancer	2.22e-06	3.59e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP19A1—esophageal cancer	2.21e-06	3.57e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EGFR—esophageal cancer	2.2e-06	3.56e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PIK3CA—esophageal cancer	2.18e-06	3.53e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HIF1A—esophageal cancer	2.17e-06	3.51e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CDKN1A—esophageal cancer	2.14e-06	3.47e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP19A1—esophageal cancer	2.13e-06	3.46e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GNG7—esophageal cancer	2.13e-06	3.45e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—esophageal cancer	2.13e-06	3.45e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CREBBP—esophageal cancer	2.12e-06	3.43e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ERBB2—esophageal cancer	2.12e-06	3.43e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—esophageal cancer	2.12e-06	3.43e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CREBBP—esophageal cancer	2.1e-06	3.4e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ADH1B—esophageal cancer	2.09e-06	3.39e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—NOS3—esophageal cancer	2.09e-06	3.38e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KDR—esophageal cancer	2.07e-06	3.36e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—esophageal cancer	2.07e-06	3.36e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP1B1—esophageal cancer	2.06e-06	3.34e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—esophageal cancer	2.05e-06	3.33e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EP300—esophageal cancer	2.04e-06	3.3e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.03e-06	3.29e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.03e-06	3.29e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—HMOX1—esophageal cancer	2.01e-06	3.26e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMP—esophageal cancer	2e-06	3.24e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALDH2—esophageal cancer	2e-06	3.23e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.97e-06	3.2e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ADH1B—esophageal cancer	1.97e-06	3.19e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.96e-06	3.18e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NOTCH1—esophageal cancer	1.95e-06	3.17e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—HMOX1—esophageal cancer	1.95e-06	3.15e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.94e-06	3.15e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.94e-06	3.15e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP19A1—esophageal cancer	1.94e-06	3.14e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MYC—esophageal cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ABCB1—esophageal cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.92e-06	3.11e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.91e-06	3.09e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—esophageal cancer	1.91e-06	3.09e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PIK3CA—esophageal cancer	1.91e-06	3.09e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTT1—esophageal cancer	1.9e-06	3.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALOX15—esophageal cancer	1.89e-06	3.07e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—esophageal cancer	1.89e-06	3.06e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HIF1A—esophageal cancer	1.89e-06	3.06e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMP—esophageal cancer	1.88e-06	3.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NOS3—esophageal cancer	1.88e-06	3.04e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP2A6—esophageal cancer	1.88e-06	3.04e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ABCB1—esophageal cancer	1.87e-06	3.03e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.86e-06	3.02e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—esophageal cancer	1.84e-06	2.99e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.83e-06	2.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CDKN1A—esophageal cancer	1.81e-06	2.93e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTO1—esophageal cancer	1.81e-06	2.93e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TPI1—esophageal cancer	1.81e-06	2.93e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.78e-06	2.89e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ENO1—esophageal cancer	1.78e-06	2.88e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS1—esophageal cancer	1.78e-06	2.88e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MYC—esophageal cancer	1.78e-06	2.88e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CREBBP—esophageal cancer	1.77e-06	2.87e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—HMOX1—esophageal cancer	1.77e-06	2.87e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—EP300—esophageal cancer	1.77e-06	2.87e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ERBB2—esophageal cancer	1.76e-06	2.84e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PSME1—esophageal cancer	1.75e-06	2.84e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PSME2—esophageal cancer	1.75e-06	2.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—esophageal cancer	1.74e-06	2.82e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—esophageal cancer	1.73e-06	2.81e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALDOB—esophageal cancer	1.73e-06	2.81e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.73e-06	2.8e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CA1—esophageal cancer	1.73e-06	2.8e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EP300—esophageal cancer	1.72e-06	2.79e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CREBBP—esophageal cancer	1.72e-06	2.78e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS2—esophageal cancer	1.72e-06	2.78e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—EP300—esophageal cancer	1.71e-06	2.77e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.7e-06	2.76e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TPI1—esophageal cancer	1.7e-06	2.76e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOTCH1—esophageal cancer	1.7e-06	2.75e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ABCB1—esophageal cancer	1.7e-06	2.75e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GAPDH—esophageal cancer	1.67e-06	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.66e-06	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CRABP1—esophageal cancer	1.65e-06	2.68e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CREBBP—esophageal cancer	1.65e-06	2.67e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PIK3CA—esophageal cancer	1.64e-06	2.66e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.63e-06	2.64e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.61e-06	2.61e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—EP300—esophageal cancer	1.59e-06	2.57e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CA2—esophageal cancer	1.58e-06	2.56e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GNG7—esophageal cancer	1.57e-06	2.55e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.57e-06	2.54e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.56e-06	2.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCND1—esophageal cancer	1.55e-06	2.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CREBBP—esophageal cancer	1.54e-06	2.5e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—NOS3—esophageal cancer	1.54e-06	2.49e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP1B1—esophageal cancer	1.51e-06	2.45e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PIK3CA—esophageal cancer	1.51e-06	2.44e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MYC—esophageal cancer	1.5e-06	2.43e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1A—esophageal cancer	1.5e-06	2.43e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB2—esophageal cancer	1.48e-06	2.4e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GNG7—esophageal cancer	1.48e-06	2.4e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—NOS3—esophageal cancer	1.47e-06	2.39e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALDH2—esophageal cancer	1.47e-06	2.39e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—esophageal cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ADH7—esophageal cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.46e-06	2.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—EP300—esophageal cancer	1.44e-06	2.34e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EP300—esophageal cancer	1.43e-06	2.31e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP19A1—esophageal cancer	1.42e-06	2.3e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.41e-06	2.29e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—esophageal cancer	1.41e-06	2.28e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTT1—esophageal cancer	1.4e-06	2.27e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.39e-06	2.25e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.38e-06	2.24e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS3—esophageal cancer	1.38e-06	2.24e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—esophageal cancer	1.35e-06	2.19e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.32e-06	2.14e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ENO1—esophageal cancer	1.31e-06	2.13e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS1—esophageal cancer	1.31e-06	2.13e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.31e-06	2.12e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCND1—esophageal cancer	1.31e-06	2.12e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PIK3CA—esophageal cancer	1.31e-06	2.12e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.3e-06	2.11e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.3e-06	2.1e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PSME2—esophageal cancer	1.29e-06	2.1e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PSME1—esophageal cancer	1.29e-06	2.1e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CREBBP—esophageal cancer	1.29e-06	2.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB2—esophageal cancer	1.29e-06	2.09e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.29e-06	2.09e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PIK3CA—esophageal cancer	1.27e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1A—esophageal cancer	1.27e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PIK3CA—esophageal cancer	1.26e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—esophageal cancer	1.26e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CREBBP—esophageal cancer	1.25e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.25e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MYC—esophageal cancer	1.24e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ENO1—esophageal cancer	1.24e-06	2e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.24e-06	2e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMP—esophageal cancer	1.23e-06	1.99e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PSME2—esophageal cancer	1.22e-06	1.97e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PSME1—esophageal cancer	1.22e-06	1.97e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—esophageal cancer	1.22e-06	1.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EP300—esophageal cancer	1.21e-06	1.95e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.2e-06	1.94e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CA—esophageal cancer	1.17e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—EP300—esophageal cancer	1.17e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.17e-06	1.89e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NOS3—esophageal cancer	1.16e-06	1.87e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CREBBP—esophageal cancer	1.14e-06	1.84e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—EP300—esophageal cancer	1.12e-06	1.82e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NOS3—esophageal cancer	1.12e-06	1.81e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.12e-06	1.81e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TPI1—esophageal cancer	1.11e-06	1.8e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.11e-06	1.8e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1A—esophageal cancer	1.1e-06	1.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CA—esophageal cancer	1.07e-06	1.73e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.07e-06	1.73e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—esophageal cancer	1.06e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CA—esophageal cancer	1.06e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.05e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MYC—esophageal cancer	1.05e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EP300—esophageal cancer	1.05e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.05e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—esophageal cancer	1.03e-06	1.67e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.03e-06	1.66e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—esophageal cancer	1.02e-06	1.66e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—esophageal cancer	1.02e-06	1.66e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.02e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NOS3—esophageal cancer	1.02e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP19A1—esophageal cancer	9.89e-07	1.6e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GNG7—esophageal cancer	9.68e-07	1.57e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HMOX1—esophageal cancer	9.57e-07	1.55e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—esophageal cancer	9.3e-07	1.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MYC—esophageal cancer	9.15e-07	1.48e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALDH2—esophageal cancer	9.07e-07	1.47e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HMOX1—esophageal cancer	9.02e-07	1.46e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—esophageal cancer	8.95e-07	1.45e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CA—esophageal cancer	8.92e-07	1.45e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—EP300—esophageal cancer	8.79e-07	1.42e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ABCB1—esophageal cancer	8.66e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CA—esophageal cancer	8.66e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—esophageal cancer	8.63e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.63e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.53e-07	1.38e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—EP300—esophageal cancer	8.5e-07	1.38e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CREBBP—esophageal cancer	8.33e-07	1.35e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CA—esophageal cancer	8.3e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS1—esophageal cancer	8.08e-07	1.31e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ENO1—esophageal cancer	8.08e-07	1.31e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PSME1—esophageal cancer	7.97e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PSME2—esophageal cancer	7.97e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CA—esophageal cancer	7.77e-07	1.26e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—EP300—esophageal cancer	7.74e-07	1.25e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NOS3—esophageal cancer	7.45e-07	1.21e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.87e-07	1.11e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—esophageal cancer	6.82e-07	1.1e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CA—esophageal cancer	6.5e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.46e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CA—esophageal cancer	6.29e-07	1.02e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CREBBP—esophageal cancer	6.14e-07	9.95e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.9e-07	9.56e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CREBBP—esophageal cancer	5.79e-07	9.38e-06	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CA—esophageal cancer	5.72e-07	9.27e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—EP300—esophageal cancer	5.67e-07	9.19e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.66e-07	9.17e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NOS3—esophageal cancer	5.5e-07	8.91e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NOS3—esophageal cancer	5.18e-07	8.39e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—esophageal cancer	5.03e-07	8.15e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—esophageal cancer	4.74e-07	7.68e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CA—esophageal cancer	4.19e-07	6.8e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—EP300—esophageal cancer	4.18e-07	6.78e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—EP300—esophageal cancer	3.94e-07	6.39e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.78e-07	6.13e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NOS3—esophageal cancer	3.39e-07	5.49e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.1e-07	5.02e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CA—esophageal cancer	3.09e-07	5.01e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.92e-07	4.72e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—EP300—esophageal cancer	2.58e-07	4.17e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.91e-07	3.09e-06	CbGpPWpGaD
